Vaccination in the EU: benefits and barriers, European Parliament Committee on the Environment, Public Health and Food Safety
Professor Mike Catchpole, Chief Scientist of ECDC, presented to the Environment, Public Health and Food Safety Committee of the European Parliament during an exchange of views on vaccination.
Understanding the association between narcolepsy and one of the 2009 adjuvanted influenza A (H1N1) vaccines
This meeting was designed to offer a place to exchange the latest information on into the development of narcolepsy following vaccination with one of the 2009 adjuvanted influenza A(H1N1) vaccines.
Workshop: Finding the balance in life-course vaccination
The main objectives of the session were to: raise awareness about the value and opportunities of life-course vaccination, build understanding of the challenges faced at decision-making level to assess such a shift, discuss the evidence necessary to help prioritising vaccinations across age groups, prompt reflection on relevant ways forward and action at EU and national level.
Influenza vaccination of health care workers - can uptake be improved?
This online course was developed because seasonal influenza vaccination of health care workers (HCWs) is recommended in Europe but vaccination uptake remains low in most countries.
Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in AustriaArchived
This paper describes the epidemiology of rotavirus (RV) in Austrian children before and during universal mass campaign.
European Parliament resolution on the evaluation of the management of H1N1 influenza in 2009-2010 in the EUArchived
The European Parliament adopted a resolution on the evaluation of the pandemic in its sitting on the 8th March 2011.
An Inactivated Cell-Culture Vaccine against Yellow FeverArchived
A double-blind, placebo-controlled, dose-escalation, phase 1 study was performed in 60 healthy subjects between 18 and 49 years of age. The two-dose regimen induced the development of neutralizing antibodies in high percentages of the subjects (from 88% to 100% of subjects depending on antigen content)”.